Effects of Dapagliflozin on Progression of Alport Syndrome

Sponsor
Nanjing University School of Medicine
Study ID
NCT06226896
Status
Active Not Recruiting

Conditions

  • Alport Syndrome

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Recently, a series of large clinical trials have confirmed the cardio-renal protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors. but few patients with hereditary nephritis were included in these studies. This study is to evaluate the effects of dapagliflozin on slowing kidney disease progression in patients with Alport syndrome.

Key Dates

Start date
Nov 15, 2023
Status verified
Sep 2024
Primary completion
Jun 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
222 participants (actual)

Arms

  • Arm: Dapagliflozin + RAS inhibitor
    In addition to ACEI/ARB treatment, patients will receive dapagliflozin 10mg once daily for 24 months.
  • Arm: RAS inhibitor only
    Patients will continue ACEI/ARB treatment for 24 months.

Primary Outcome Measure

Change of eGFR [ Time Frame: 24 months ]

Related Studies